Table 2.
Drugs used in experimental models for ex-vivo defatting of steatotic livers.
| Model | n | Perfusion | Length of Perfusion (hours) | Defatting Agents | Main Outcomes | |
|---|---|---|---|---|---|---|
| Nagrath et al., 2009 [18] | rat | 7 | NMP | 3 | combination of visfatin, forskolin, hypericin and nuclear receptor ligands (GW7, GW5, scoparone) | decrease of TG rate improvement of bile production |
| Liu et al., 2013 [25] |
rat | NA | SNMP | 6 | combination of amino acids, visfatin, forskolin, hypericin and nuclear receptor ligands (GW7, GW5, scoparone) | higher rate of TG (non significance) |
| Raigani et al., 2020 [26] | rat | 6 | NMP | 6 | combination of amino acids, visfatin, forskolin, hypericin and nuclear receptor ligands (GW7, GW5, scoparone) | decrease of pro inflammatory markers (NF- κB, TNF-α, IL-6) decrease of pro-apoptotic markers (CASP3, CD95) decrease of combined VLDL/LDL level |
| Taba Taba Vakili et al., 2016 [27] | mice | 4 | NMP | 4 | glial cell line–derived neurotrophic factor |
reduction of TG content in liver no liver damage (no increase of apoptosis) |
| Banan et al., 2016 [31] |
human discarded livers | 2 | NMP | 8 | L-carnithine and exendin-4 | decrease of TG and LDL level in the perfusate reduction of Mas |
| Boteon et al., 2019 [32] |
human livers discarded | 5 | NMP | 12 | combination of L-carnithine, visfatin, forskolin, hypericin and nuclear receptor ligands (GW7, GW5, scoparone) | decrease of T-TG level decrease of MaS increase of P-TG level higher bile production |
LDL: low-density lipoprotein; MaS: macrovesicular steatosis; NMP: normothermic perfusion; P-TG: SNMP: subnormothermic perfusion; TG: triglycerides; T:TG: tissue-TG; VLDL: very low-density lipoprotein.